15 Jul 2024 by admin in UncategorizedComments Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma
15 Jul 2024 by admin in UncategorizedComments Eluminex Biosciences Announces First Patient Dosed in the Phase 1b LOTUS Trial of the Novel Trispecific Fusion Antibody EB-105 in Diabetic Macular Edema (DME)
09 Jul 2024 by admin in UncategorizedComments nterius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
01 Jul 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer July 1, 2024
